PREDQ (Predictive Technology Group) YoY EBITDA Growth: 48.48% (As of Mar. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Predictive Technology Group YoY EBITDA Growth?

Predictive Technology Group PREDQ -90.00% YoY EBITDA Growth is 48.48% as of Mar. 2021.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Predictive Technology Group's YoY EBITDA Growth for the quarter that ended in Mar. 2021 was 48.48%.

Predictive Technology Group's EBITDA per Share for the three months ended in Mar. 2021 was $-0.02.

Predictive Technology Group YoY EBITDA Growth Related Terms

Predictive Technology Group YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Predictive Technology Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Predictive Technology Group YoY EBITDA Growth Chart

Predictive Technology Group Annual Data
Trend Aug06 Aug07 Jun16 Jun17 Jun18 Jun19 Jun20
YoY EBITDA Growth
Get a 7-Day Free Trial 93.84 44.44 -540.00 -34.38 -581.40

Predictive Technology Group Quarterly Data
Nov07 Feb08 May08 Jun16 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -230.00 -385.71 54.05 82.29 48.48

Predictive Technology Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Predictive Technology Group's YoY EBITDA Growth for the fiscal year that ended in Jun. 2020 is calculated as:

YoY EBITDA Growth (A: Jun. 2020 )
=(EBITDA per Share (A: Jun. 2020 )-EBITDA per Share (A: Jun. 2019 ))/ | EBITDA per Share (A: Jun. 2019 ) |
=(-0.293--0.043)/ | -0.043 |
=-581.40 %

Predictive Technology Group's YoY EBITDA Growth for the quarter that ended in Mar. 2021 is calculated as:

YoY EBITDA Growth (Q: Mar. 2021 )
=(EBITDA per Share (Q: Mar. 2021 )-EBITDA per Share (Q: Mar. 2020 )) / | EBITDA per Share (Q: Mar. 2020 )) |
=(-0.017--0.033)/ | -0.033 |
=48.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 48.48% mean?
Predictive Technology Group (PREDQ) has a YoY EBITDA Growth of 48.48% as of Mar. 2021. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Predictive Technology Group and its competitors.
Is Predictive Technology Group's YoY EBITDA Growth too high?
Predictive Technology Group's current YoY EBITDA Growth is 48.48%.
How does Predictive Technology Group's YoY EBITDA Growth compare to GLMD and RCAR?
Predictive Technology Group's YoY EBITDA Growth of 48.48% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Predictive Technology Group and its competitors. Predictive Technology Group's current YoY EBITDA Growth is 48.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predictive Technology Group stock overvalued right now?
Predictive Technology Group (PREDQ) has a current YoY EBITDA Growth of 48.48%. The current YoY EBITDA Growth is 48.48%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Predictive Technology Group (PREDQ), the current YoY EBITDA Growth is 48.48% as of Mar. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Predictive Technology Group Business Description

Address 2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109
Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.